ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552
Debt
Debt-to-Equity Ratio1.76
Current Ratio4.92
Quick Ratio3.60
Price-To-Earnings
Trailing P/E Ratio-2.61
Forward P/E Ratio-3.72
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.76 million
Price / Sales9.94
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book5.61
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-43,750,000.00
Net Margins-101.93%
Return on Equity-88.31%
Return on Assets-25.76%
Miscellaneous
Employees295
Outstanding Shares45,320,000
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.08. The biotechnology company earned $4.04 million during the quarter, compared to analyst estimates of $7.47 million. ADMA Biologics had a negative net margin of 101.93% and a negative return on equity of 88.31%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
3 analysts have issued 1 year price targets for ADMA Biologics' shares. Their predictions range from $5.00 to $10.00. On average, they anticipate ADMA Biologics' share price to reach $7.50 in the next twelve months. View Analyst Ratings for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include La Jolla Pharmaceutical (LJPC), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Scholar Rock (SRRK), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Mesoblast (MESO), CASI Pharmaceuticals (CASI), Vericel (VCEL), Surface Oncology (SURF), Nightstar Therapeutics (NITE), MeiraGTx (MGTX), PDL BioPharma (PDLI) and NanoString Technologies (NSTG).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 41)
- Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 70)
- Mr. Brian Lenz, VP & CFO (Age 46)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Has ADMA Biologics been receiving favorable news coverage?
Media headlines about ADMA stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ADMA Biologics earned a news impact score of 0.13 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.37 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are ADMA Biologics' major shareholders?
ADMA Biologics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.60%), BlackRock Inc. (0.09%), JPMorgan Chase & Co. (0.09%), Element Capital Management LLC (0.06%) and Spark Investment Management LLC (0.05%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.
Which institutional investors are buying ADMA Biologics stock?
ADMA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Element Capital Management LLC, Spark Investment Management LLC and BlackRock Inc.. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $4.99.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $224.77 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
